AbbVie Celebrates its Debut as an Independent Biopharmaceutical Company

On Wednesday, January 2, 2012, executives and guests of AbbVie (NYSE: ABBV) will visit the New York Stock Exchange (NYSE) to celebrate the recent completion of its separation from, Abbott Laboratories (NYSE: ABT).  

Shares of AbbVie will begin trading on the NYSE on January, 2, 2013, under the ticker symbol “ABBV”.

To celebrate this milestone, AbbVie Chairman and Chief Executive Officer Richard A. Gonzalez will ring the NYSE Opening Bell, joined by members of the company’s executive management team.  

About AbbVie (NYSE: ABBV)

AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or check out careers on our Facebook page.